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medication of all patients and 1 hour after that echocardiograpdic
parameters was measured again, and the results were compared.
RESULTS: Peak pulmonary artery pressure and pulmonary accel-
eration time (PAT) signiﬁcantly improved 1 hour after 100 mgoral
single dose of Sildenaﬁl (p < 0.005, 95% CI 5.41–22.93 and
p = 0.005 95% CI -12.89–2.95 respectively). In addition
although the right heart dimensions (right atrium & ventricle)
showed a trend toward improvement, but were not statistically
signiﬁcant (p = 0.135, p = 0.08 respectively). CONCLUSION:
These results suggest that Sildenaﬁl has a acute signiﬁcant
improvement effect on PAP and PAT in patients with PPH.
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OBJECTIVES: Community Acquired Pneumonia (CAP) is a
leading cause of hospitalisation and mortality in industrialised
countries. This study was an economic evaluation comparing
moxiﬂoxacin with a combination of levoﬂoxacin plus ceftriaxone
in patients hospitalised with CAP in Germany. METHODS: The
MOTIV trial was a multinational, prospective, randomized,
double-blind study in adults with CAP requiring hospitalisation
and parenteral antibiotic therapy. Patients were randomised to
either moxiﬂoxacin (N = 368), or levoﬂoxacin plus ceftriaxone
(N = 365) and received sequential treatment with intravenous
followed by oral antibiotics for 7–14 days. The primary effective-
ness endpoint was clinical response 5–7 days after completion of
treatment. Resource use recorded included length of stay, ward
type, investigations and procedures performed and dose and
frequency of study drug used. Costs were calculated from a
German hospital perspective, drug costs were taken from the Rote
Liste and other costs from a recent publication. A stochastic
sensitivity analysis was performed. RESULTS: Mean age was 65
years (range 18–101) and 58% of patients had severe CAP. The
percentage of patients reporting clinical response (moxiﬂoxacin:
80%, comparator: 84%) met criteria for clinical equivalence so a
cost-minimisation analysis was performed. Mean per patient cost
was €2190 (95% CI: €1954, €2463) for the moxiﬂoxacin group,
and €2619 (95% CI: €2422, €2832) for the comparator group,
difference (-€430, 95%CI: -€740, -€138).Medication costs were
signiﬁcantly lower for moxiﬂoxacin than comparator (-€470,
95% CI: -€522, -€421) but accounted for only 15–30% of total
costs. Subgroup analysis of patients with COPD, cardiovascular
disease, microbiologically proven pneumonia, or severe CAP at
baseline produced consistent ﬁndings. Average cost was sensitive
to price paid for study drugs and the daily cost of hospital stay.
CONCLUSION: Treatment with moxiﬂoxacin was signiﬁcantly
less costly than treatment with levoﬂoxacin plus ceftriaxone, with
no clinically signiﬁcant difference in outcomes achieved.
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OBJECTIVES: Chronic obstructive pulmonary disease (COPD)
is one of the most common chronic and disabling diseases
worldwide. The objectives of this study were to measure the
societal costs of COPD including both direct and indirect costs,
and to estimate the costs for different severity grades of disease
according to changed Swedish guidelines. METHODS: A well-
deﬁned and representative cohort of subjects was used to
examine the costs of COPD. Regular telephone interviews were
done with 212 subjects derived from the OLIN-Studies in
northern Sweden. The severity grades of COPD were divided
according to changed Swedish guidelines, and furthermore Mild
COPD (FEV1 50–79% of predicted) was divided into three
sub-groups, Mild I, II and III. RESULTS: A positive relation-
ship was found between costs and severity grades of COPD,
patients with lower FEV1 % of predicted normal being signiﬁ-
cantly more expensive. Furthermore, the total costs differed sig-
niﬁcantly between the Mild and Pre-clinical severity groups,
from a mean value of SEK 2,513 per subject in the Pre-clinical
group to SEK 28,463 for subjects having FEV1 50–59% of
predicted. The same pattern was found both in direct and indi-
rect costs. Costs for medicines and hospitalisations increased
signiﬁcantly according to FEV1 values in the Mild and Pre-
clinical groups of disease. Costs for disability pension among
indirect costs showed a similar trend. The annual total costs for
Severe (FEV1 < 30% of predicted), Moderate (30–49%), Mild I
(50–59%), Mild II (60–69%), Mild III (70–79%), and Pre-
clinical COPD (>79%) were SEK 183,474, 70,609, 28,463,
11,527, 6,287 and 2,513, respectively. CONCLUSION: Large
variations were found in both the level and breakdown of costs
for COPD, mainly depending on the severity of the disease.
When dividing mild COPD into three different severity grades
of disease, we also found a positive relationship between costs
and severity of disease.
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OBJECTIVES: Assessment of the inﬂuence of nicotine addic-
tion, time of duration and severity of COPD on the frequency of
exacerbations. METHODS: 71 patients with moderate-to-
severe COPD (30 with moderate and 41 with severe) were
enrolled to the study. The smoking status, FEV1 value, time of
duration of COPD, and a one-year history of incidence of exac-
erbations were assessed in all the subjects. The relationship
between the number of exacerbations and the studied features
was evaluated with the regression model. RESULTS: Thirteen
(18.3%) subjects were current smokers, 9 (12.7%) had never
smoked and 50 (70%) had smoked in the past. The mean inten-
sity of cigarette smoking amounted to 34.7 pack-years [CI:
28.7–40.7]. The mean time of COPD duration was 9.2
[CI: 7.7–10.8] years, the mean frequency of exacerbation—3.1
[CI: 2.5–3.6] per year, and the mean % value of FEV1 was
48.1% [CI: 43.7–52.5]. There was no signiﬁcant relationship
between the frequency of exacerbations and the number of
pack-years, smoking status, % value of FEV1 and severity of
COPD. A signiﬁcant correlation was observed between the time
of duration of COPD and average number of exacerbations
(r = 0.31, p = 0.009). It was calculated that each successive year
of COPD duration is associated with 3% accumulation of exac-
erbation risk (determination coefﬁcient—R2 = 0.03). CON-
CLUSION: Long-time duration of COPD is related to a
signiﬁcant increase of the risk of COPD exacerbations—the key
drivers in the overall costs of the disease.
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